Introduction {#s1}
============

Neuropsychiatric disorders such as schizophrenia, mood disorders, or drug addiction, represent a huge burden on society, greatly impairing the health of those affected. During the last half-century, considerable progress has been made to understand, prevent, and treat such conditions. However, treatment options are still far from optimal in terms of efficacy and specificity, and there remain important untreatable maladaptive phenotypes and treatment-resistant patients. To solve this issue, basic and applied research has tried to identify new altered neuropsychological mechanisms suitable to promote new therapeutic strategies (Cuthbert, [@B31]). In this quest, the discovery of adult hippocampal neurogenesis (Altman and Das, [@B4]) and its health implications (Kempermann, [@B53]) has opened new vistas upon innovative pharmacotherapies that could ameliorate impaired hippocampal function. Among the many ways proposed to accomplish such an improvement, cannabidiol (CBD) has recently stood out as a promising compound to be taken into consideration. In light of this, the following mini-review article aims to: (1) summarize the available evidence describing the modulation of adult hippocampal neurogenesis by CBD; to (2) provide a prospective collection of the responsible mechanisms; and (3) to detail the presumed therapeutic potential of this phytocannabinoid *via* the modulation of adult neurogenesis.

Cannabidiol {#s1-1}
-----------

CBD is one of the most abundant constituents of the *Cannabis sativa* plant. Unlike Δ^9^-tetrahydrocannabinol (THC), CBD is devoid of psychotomimetic and rewarding effects (Ligresti et al., [@B63]), and is well tolerated in humans (Chesney et al., [@B29]). CBD is thought to interact with several molecular targets (Campos et al., [@B1100]). Its main targets within the central nervous system are comprehended by the activation of 5-hydroxytryptamine 1A (5-HT~1A~), transient potential vanilloid 1 (TRPV1), G-protein 55 (GPR55) and peroxisome proliferator-activated gamma (PPARγ) receptors, as well as the antagonism of adenosine reuptake (Turner et al., [@B113]). Despite initial controversy about its endocannabinoid targets (Zlebnik and Cheer, [@B118]), recent evidence also supports CBD as a negative allosteric modulator of cannabinoid receptors 1 and 2 (CB1, CB2) at physiologically relevant concentrations (Laprairie et al., [@B60]; McPartland et al., [@B73]; Martínez-Pinilla et al., [@B72]; Navarro et al., [@B78]; Tham et al., [@B111]). Also, CBD reduces anandamide (AEA) metabolism by inhibiting fatty acid amide hydrolase (FAAH) activity (De Petrocellis et al., [@B32]). Consequently, CBD is an efficient anxiolytic (Fogaça et al., [@B43]) and there is evidence suggesting that it possesses anti-inflammatory (Atalay et al., [@B8]), neuroprotective (Campos et al., [@B23]), antidepressant (Sales et al., [@B95]), anti-relapse (Gonzalez-Cuevas et al., [@B47]), pro-cognitive (Osborne et al., [@B83]) and antipsychotic (Renard et al., [@B91]) effects. Accordingly, CBD has been proposed as a novel therapeutic strategy for different mental disorders such as drug addiction (Calpe-López et al., [@B20]), depression (Silote et al., [@B103]), or schizophrenia (Elsaid and Le Foll, [@B38]). Notwithstanding the foregoing, CBD has a formidably complex pharmacology, and therefore, we lack a clear understanding of the molecular and neuroplastic consequences of CBD treatments. With such a pool of targets, numerous hypotheses have tried to explain CBD's therapeutic mechanisms in each of the psychiatric models addressed. The modulation of neuronal network dynamics in the mesolimbic system *via* 5-HT~1A~ activation (Norris et al., [@B81]) is positioned as the best approximation to CBD's anti-craving actions (Katsidoni et al., [@B52]; Bi et al., [@B14]; Galaj et al., [@B44]). On the other hand, the presumed motivational consequences of *in vivo* CBD's CB1 effects remain unclear. Recent reports show that CBD modulation of cocaine-seeking reinstatement, but not operant intake, depends on CB1 receptor activation (Galaj et al., [@B44]; Lujan et al., [@B67]). Therefore, indirect CB1 activation through FAAH blockade, rather than CB1 negative allosteric modulation, is a more plausible mechanism for the anti-craving effects of CBD. In the case of mood and anxiety-related disease models, the activation of ventromedial prefrontal cortex 5-HT~1A~ and CB1 receptors (Linge et al., [@B64]; Sartim et al., [@B97]), and the neuroprotection against inflammatory and oxidative brain insults (Campos et al., [@B23]) are the main mechanism candidates. Lastly, diverse studies have also pointed to the pro-neurogenic effects of CBD, as reviewed below.

Adult Hippocampal Neurogenesis in the Mammalian Brain {#s1-2}
-----------------------------------------------------

Adult hippocampal neurogenesis encompasses a complex, multistep process comprehending the proliferation, survival, differentiation/maturation, and functional integration of newborn neurons residing in the subgranular zone (SGZ) of the dentate gyrus (DG; Kuhn et al., [@B56]; [Figure 1A](#F1){ref-type="fig"}). It is detailed in most mammals (Amrein, [@B5]), but its existence in humans has been hotly debated due to the critical dependence on ^14^C labeling (Sorrells et al., [@B105]). However, the latest evidence suggests that adult hippocampal neurogenesis in humans is abundant even in the senescence (Boldrini et al., [@B17]; Tobin et al., [@B112]) and that previous discrepancies were probably due to tissue processing protocols or neurological illness of the tissue donors (Moreno-Jiménez et al., [@B76]).

![The pro-neurogenic effects of cannabidiol (CBD) and its functional relevance. **(A)** Adult hippocampal neurogenesis originates from type 1 precursor cells that might differentiate into granule neurons (Kriegstein and Alvarez-Buylla, [@B701]). The newly generated cells can be stimulated *via* GABAergic, endocannabinoid- and serotonin-dependent mechanisms (Encinas et al., [@B39]; Prenderville et al., [@B87]). The proliferation phase ends just after precursor cells exit the cell cycle. As early as 1 day after such an event, newborn neurons start expressing the postmitotic marker NeuN, which then declines as most newborn cells are eliminated before they become functional (survival phase; Kempermann et al., [@B54]). Within days after generation, newborn neurons send their axons to cornu ammonis 3 (CA3), where they form proper synapses (Sun et al., [@B107]). In the next phase, newborn neurons mature as the excitatory nature of GABA inputs shift into the standard depolarizing profile. Finally, new mature neurons go through a phase of increased synaptic plasticity, which in turn promotes its final integration into the hippocampal circuitry (functional integration phase; Ge et al., [@B45]). The effects of CBD are preferentially focused on the post-mitotic stages of the neurogenic process, whenever it facilitates neuronal maturation and impedes early neuronal death.**(B)** The pro-neurogenic effects of CBD are orchestrated by the eCB system. Furthermore, CBD upregulates different molecular components of downstream pathways usually associated with the eCB-driven facilitation of adult neurogenesis. Final molecular effectors of the protein synthesis and survival machinery of the hippocampus such as brain-derived neurotrophic factor (BDNF), calbindin, MAP-2, synapsin 1, and the activation of protective peroxisome proliferator-activated gamma (PPARγ) receptors, are also found upregulated after CBD subchronic treatments. **(C)** The figure represents a simplified vision of the hippocampal neurocircuitry functionally coupled to the neurogenic state of the dentate gyrus (DG). The hippocampus (ventral part) sends direct projections to the GABAergic interneurons of the BNST that, in turn, tune-down the hypothalamus--pituitary--adrenal (HPA) axis (Snyder et al., [@B104]). Direct projections from the hippocampus to the mPFC promote stress sensitivity (Padilla-Coreano et al., [@B84]), and mediate antidepressant effects (Bagot et al., [@B10]). Ventral hippocampal outputs to the BLA are involved in the feedforward inhibition of fear and anxiety-related responses (Bazelot et al., [@B12]). Finally, the hippocampus can indirectly influence VTA DA release in motivated tasks by activating medium spiny neurons of the NAc (Britt et al., [@B19]). Abbreviations: GFAP, glial fibrillary acidic protein; Mol, molecular layer; GCL, granule cell layer; AEA, anandamide; mPFC, medial prefrontal cortex; NAc, nucleus accumbens; BLA, basolateral amygdala; BNST, bed nucleus of the stria terminalis; VTA, ventral tegmental area. Created with [Biorender.com](https://Biorender.com).](fnbeh-14-00109-g0001){#F1}

During their development, adult-born neurons modulate DG functions that orchestrate diverse behaviors. Newborn neurons act as independent encoding units that can inhibit the activity of mature granule cells (Drew et al., [@B37]) and dampen overall DG excitability (Ikrar et al., [@B50]). Given the participation of hippocampal function in mood, cognition, and motivation, adult hippocampal neurogenesis is involved in different neuropsychological processes in physiological and pathological conditions (Mandyam and Koob, [@B70]). For example, patients with depression exhibit decreased levels of neurogenesis (Lucassen et al., [@B66]). Neurogenesis ablation increases innate anxiety-like behaviors (Revest et al., [@B92]) and depressive-like symptoms (Wu et al., [@B116]) in animal models. And more importantly, anti-depressant drugs increase neurogenesis, an effect that is required to observe some of its behavioral effects in rodents (Santarelli et al., [@B96]). Such relations are thought to be due to the newborn neuron regulation of hippocampal inhibitory control over the hypothalamus--pituitary--adrenal (HPA) axis. The ventral part of the hippocampus has also been related to emotional control. This region shares regulatory projections to canonical emotional-processing structures such as the basolateral amygdala or the medial prefrontal cortex that are key to modulate fear-associated memories and anxiety (Felix-Ortiz et al., [@B42]; Padilla-Coreano et al., [@B84]) and are regulated by neurogenesis (Temprana et al., [@B110]; [Figure 1C](#F1){ref-type="fig"}). Interestingly, it is now described that pattern separation, a brain computational mechanism dependent on newborn neurons (Leutgeb et al., [@B61]; Sahay et al., [@B94]) also allows for the discrimination of emotional states experienced during memory creation (Redondo et al., [@B88]), thus granting adult hippocampal neurogenesis a way to modulate emotional memories retrieval and storage (Anacker and Hen, [@B6]). There is debate as to whether such functional implication could represent a caveat of pro-neurogenic therapeutics, as enhanced pattern separation processes may promote proactive interference (see Epp et al., [@B40]; Tello-Ramos et al., [@B109]).

Additionally, the circuitry involved in the regulation of mood and stress overlaps with the brain circuitry affected by motivation disorders (Koob, [@B55]; Volkow et al., [@B65]). Hence, extensive evidence posits adult hippocampal neurogenesis as an additional component of drug addiction etiology (Castilla-Ortega et al., [@B25]; Barr et al., [@B11]). In this sense, rats with experimentally-reduced neurogenesis consume more cocaine and work harder to obtain the drug (Noonan et al., [@B80]; Deroche-Gamonet et al., [@B35]). Conversely, pharmacological induction of adult neurogenesis facilitates the forgetting of cocaine-contextual memories (Ladrón de Guevara-Miranda et al., [@B58]). Other drugs, such as alcohol, induce persistent reductions in adult neurogenesis in rodents (Spear, [@B106]), primates (Taffe et al., [@B108]), and humans, as shown by *post mortem* samples from alcohol abusers (Dhanabalan et al., [@B36]). Finally, the neonatal ventral hippocampal lesion rat model, which irreversibly lessens adult neurogenesis, has been used to reveal the participation of adult neurogenesis in the pathogenesis of dual diagnosis schizophrenia (Chambers and Self, [@B28]). This relation suggests that neurogenic deficits may also underlie positive-like, negative, and cognitive symptoms of schizophrenia in rodent models (Chambers, [@B26]; Sentir et al., [@B100]). Overall, a wealth of literature supports the relevance of adult neurogenesis in preclinical models of mood and anxiety disorders, as well as drug addiction or schizophrenia, while opens a new window of therapeutic opportunities aimed to ameliorate impaired hippocampal function.

Promoting Neurogenesis with Cannabidiol {#s2}
=======================================

Preclinical Evidence {#s2-1}
--------------------

Considering that the endocannabinoid (eCB) system exerts important functions in the regulation of neuronal generation and survival (Aguado et al., [@B1]), the Kempermann's group firstly explored the possibility that a cannabinoid like CBD could enhance the survival of DG newborn neurons in mice (Wolf et al., [@B115]). The pioneering study showed that a CBD-enriched diet increased co-localized immunoreactivity of 5-bromo-2′-deoxyuridine (BrdU) and *neuronal nuclei* (NeuN). Moreover, the authors reported an interesting opposition to the effects of THC on this measure. Months later, Demirakca et al. ([@B34]) similarly proposed these pro-neurogenic actions of CBD in humans. Since then, researchers have echoed these investigations, finding a remarkable result consistency in the pro-neurogenesis induced by CBD ([Table 1](#T1){ref-type="table"}).

###### 

Literature assessing the effects of cannabidiol (CBD) in adult hippocampal neurogenesis.

  Reference                        Animal, cell line                    CBD treatment protocol          Markers                                     Effect              Experimental condition                
  -------------------------------- ------------------------------------ ------------------------------- ------------------------------------------- ------------------- ------------------------------------- --
  Wolf et al. ([@B115])            C57BL/6 female mice                  CBD-enriched diet, 6 weeks      BrdU/Nestin/DCX^--^ (early proliferation)   --                  --                                    
                                                                                                        BrdU/Nestin/DCX^+^ (late proliferation)     ↓                   --                                    
                                                                                                        BrdU/NeuN (late survival)                   ↑                   --                                    
  Esposito et al. ([@B41])         Sprague--Dawley male rats            10 mg/kg, i.p., 15 days         DCX                                         ↑                   Aβ-inoculated rats                    
  Campos et al. ([@B24])           C57BL/6 male mice                    30 mg/kg, i.p., 14 days         DCX                                         ↑                   Naive, chronic unpredictable stress   
                                                                                                        BrdU/NeuN                                   ↑                   Control                               
                                   Hippocampal HiB5 progenitors         50, 100, 250, 500 nM, 18 h      BrdU/NeuN (proliferation)                   100, 250 mg/kg: ↑   --                                    
                                                                                                                                                    50, 500 mg/kg:--                                          
  Shinjyo and Di Marzo ([@B102])   Mouse neural stem/progenitor cells   1 μM, 2 days                    Nestin                                      ↑                   --                                    
  Schiavon et al. ([@B99])         Swiss CD-1 male mice                 3 and 30 mg/kg, i.p., 15 days   DCX (proliferation)                         3 mg/kg: ↑          --                                    
                                                                                                                                                    30 mg/kg: ↓                                               
  Mori et al. ([@B77])             C57BL/6 male mice                    10 mg/kg, i.p., 3 days          DCX                                         ↑                   Ischemic mice                         
                                                                                                        MAP-2 (dendritic maturation)                ↑                   Ischemic mice                         
  Fogaça et al. ([@B43])           C57BL/6 male mice                    30 mg/kg, i.p., 14 days         DCX                                         --                  Control                               
                                                                                                                                                    ↑                   Chronic unpredictable stress          
                                                                                                        DCX-tagged cell migration                   --                  Control                               
                                                                                                                                                    ↑                   Chronic unpredictable stress          
                                                                                                        BrdU/NeuN                                   --                  Control                               
                                                                                                                                                    ↑                   Chronic unpredictable stress          
  Luján et al. ([@B69])            Swiss CD-1 male mice                 20 mg/kg, i.p., 10 days         BrdU/NeuN                                   ↑                   Control and cocaine-consuming mice    
                                                                                                        DCX                                         ↑                   Cocaine-consuming mice                
  Luján et al. ([@B68])            Swiss CD-1 male mice                 10, 20 mg/kg, i.p., 10 days     BrdU/NeuN                                   ↑                   Control and cocaine-consuming mice    
                                                                                                        DCX                                         ↑                   Control and cocaine-consuming mice    
  Bis-Humbert et al. ([@B15])      Sprague-Dawley male rats             3, 10, 30 mg/kg, i.p., 6 days   NeuroD                                      --                  --                                    

*In vivo measures of BrdU incorporation or Ki67 not accompanied by a neuronal marker (e.g., NeuN) were not considered, given the difficulty to differentiate from the proliferation of non-neuronal cellular lineages. Abbreviations: BrdU, 5-bromo-2′-deoxyuridine; NeuN, neuronal nuclei; DCX, doublecortin; MAP-2, microtubule-associated protein 2. --, no change found; ↑, increase; ↓, decrease*.

Much of the preclinical work aimed at delineating the pro-neurogenic profile of CBD has mainly utilized two immunostaining observables: doublecortin (DCX) and BrdU/NeuN. Due to the prolonged presence of both markers in different stages of the neurogenesis process (for a review see Kempermann et al., [@B54]), it is difficult to elucidate the phase specificity of CBD changes. CBD increased BrdU/NeuN co-localization from 1 month after the injection of the thymine incorporation tracer (Wolf et al., [@B115]; Fogaça et al., [@B43]), a measure of late survival, to as early as 7 days (Luján et al., [@B69], [@B68]), a correlate of early differentiation. The same consistency has been found using DCX. Following the same treatment protocol, CBD increased DCX staining from 7 days (Luján et al., [@B68]) to 1 month (Luján et al., [@B69]) after the last CBD injection. But in the work of Wolf et al. ([@B115]), CBD did not enhance, and even reduced, neural progenitor cell (BrdU/Nestin-expressing type 1/2 cells) proliferation. More studies analyzing markers of neural progenitor cell proliferation are needed but, these results could imply that CBD pro-neurogenic effects would take place after newborn neurons are generated, and not before ([Figure 1B](#F1){ref-type="fig"}). This goes in agreement with molecular findings reflecting the facilitating effects of CBD on postmitotic neuronal survival, differentiation, and maturation. The brain-derived neurotrophic factor (BDNF) positively regulates newborn neuron survival in the DG (Waterhouse et al., [@B114]), and CBD increases BDNF protein content within the hippocampus (Mori et al., [@B77]; Luján et al., [@B69]; Sartim et al., [@B98]; Sales et al., [@B95]). Calbindin, a Ca^2+^-binding protein used as a marker of mature neurons (Brandt et al., [@B18]), is also increased in the hippocampus of CBD-treated rats (Esposito et al., [@B41]). This idea has been further corroborated by the discovery that CBD activates different survival and synaptic remodeling cascades such as ERK1/2-CREB (Luján et al., [@B69]), GSK3β and PSD95 (Campos et al., [@B24]) or PI3K/mTOR/p70S6K (Renard et al., [@B90]; Giacoppo et al., [@B46]; Lanza Cariccio et al., [@B59]).

CBD pro-neurogenesis also shows great consistency across doses. Literature findings report increases in neuronal proliferation and differentiation after CBD doses ranging from 3 to 30 mg/kg, usually after prolonged treatments (≥10 days; [Table 1](#T1){ref-type="table"}). Despite this, at least two studies point to an inverted U-shaped dose-response curve effect. *in vitro*, Campos et al. ([@B24]) described that CBD enhanced neuronal proliferation at medium concentrations (100, 250 nM), but these effects disappeared at lower (50 nM) or higher doses (500 nM). Similarly, Schiavon et al. ([@B99]) showed that neuronal proliferation enhancement (here assessed by DCX) could only be observed after low (3 mg/kg) but not high (30 mg/kg) doses *in vivo*. Inverted U-shaped dose-response curves usually suggest the participation of multiple pharmacological mechanisms. In this way, it has already been described that CBD also exerts a similar anxiolytic dose-response curve (for a review see Jurkus et al., [@B51]) and that it is due to the interaction of 5-HT~1A~ and TRPV1 mechanisms (Campos and Guimarães, [@B21]). Therefore, one of the first neurogenic mechanisms that were evaluated consisted of the activation of 5-HT~1A~ receptors. However, CBD-induced proliferation in HiB5 hippocampal progenitor cells was not blocked by a 5-HT~1A~ antagonist (Campos et al., [@B24]) and so, an alternative candidate was considered: the eCB system.

Evaluating CBD's Endocannabinoid Mechanisms to Promote Neurogenesis {#s2-2}
-------------------------------------------------------------------

The eCB system stands out as a key regulator of newborn neuron generation, survival, maturation, and functional integration in the adult hippocampus. Neural progenitor cells, and their descendants, express a functional eCB system and are subject to the effects of endocannabinoid signaling (Prenderville et al., [@B87]). CB1 agonists induce neural proliferation and differentiation in the DG (Andres-Mach et al., [@B7]), which are also attenuated in CB1^−/−^ mice (Aguado et al., [@B2]; Zimmermann et al., [@B117]). The same has been detailed for CB2 receptors (Palazuelos et al., [@B85]; Avraham et al., [@B9]), although in a more complicated fashion (Rodrigues et al., [@B93]; Mensching et al., [@B74]). That is, CB1 receptors participate in the maintenance of adult neurogenesis, whereas CB2 receptors seem to promote the recovery from allostatic neurogenic states (Oddi et al., [@B82]). Furthermore, the intricate downstream cellular pathways engaged by cannabinoid receptors, mainly converging in Akt/mTORC and MAPK/CREB pathways, are critically involved in cell proliferation, differentiation, and survival and are required for endocannabinoids to exert its pro-neurogenic effects (Prenderville et al., [@B87]).

Given the mechanistic interactions between CBD and eCB system, a plausible hypothesis originated stating that CBD increases adult neurogenesis by modulating the eCB system. Accordingly, *in vitro* and *in vivo* evidence has suggested such interplay. The first evidence was given by Wolf et al. ([@B115]). In their study, a CBD-enriched diet facilitated newborn neuron survival, an effect prevented in CB1^−/−^ mice. The seminal work of Campos et al. ([@B24]) further explored this idea and tested which molecular mechanisms could be involved *in vitro*. CB1 and CB2 antagonists prevented the pro-neurogenic effect of CBD in hippocampal HiB5 progenitor cells. Furthermore, CB1 and CB2 receptor agonists, as well as eCB degradation inhibitors mimicked the pro-neurogenic effects of CBD. Interestingly, CBD effects were abrogated when the FAAH was inhibited. Combined, these results imply that the pro-neurogenic effects of CBD depending on the increase of AEA concentration. Crucially, CBD is an inhibitor of the FAAH and is well known to increase AEA concentration (Bisogno et al., [@B16]; De Petrocellis et al., [@B32]; Leweke et al., [@B62]; Petrosino et al., [@B86]). Note that, in this case, the CBD-induced negative allosteric modulation of CB1 receptors should not account for these results, as they rely on the facilitation of CB1 function. Alternatively, CBD can also increase the protein content of CB1 receptors in the hippocampus (Luján et al., [@B69]). Recently, a similar mechanism was revealed *in vivo*. After a CBD treatment in chronically stressed mice, neuronal differentiation, and late survival were found to be increased in CBD-treated mice (Fogaça et al., [@B43]). Such pro-neurogenic effects depended on CB1 and CB2 receptor activation, insofar respective antagonists abolished said increase. Intriguingly, CB1 antagonism only prevented the DCX-labeled neuronal differentiation increase whereas the CB2 antagonist precluded the increment of both, neuronal differentiation and late survival (BrdU/NeuN; Fogaça et al., [@B43]). Regarding this divergence, previous works have indicated that CB1 receptors may be implicated in maintaining basal adult neurogenesis, while CB2 receptors might be more physiologically relevant in coping with neurotoxic brain insults (Oddi et al., [@B82]). In the study of Fogaça et al. ([@B43]), possibly the CB2 outshined CB1 receptors because its relative contribution was exclusively performed in chronically-stressed mice. So far, the differential role of CB1 and CB2 receptors in the pro-neurogenic effects of CBD in normal and allosteric conditions has not been explored enough, and more studies are needed to address this question. Altogether, studies interrogating the eCB system in conditions in which CBD produced pro-neurogenic effects have all encountered a suggesting implication. Although promising, there remain important gaps to be filled. For instance, no data is available as to the eCB-specific downstream signaling pathways recruited by cannabinoid receptors that would be facilitating neuronal survival and differentiation, despite some approximations in this regard (Luján et al., [@B69]). Furthermore, there also remain some unexplored CBD mechanisms with potential pro-neurogenic properties, such as GPR55 activation for coping reduction of neurogenesis in response to inflammatory insults (Hill et al., [@B48]). Noteworthy, a protective interaction involving neuroinflammation processes has been already observed, showing that CBD-mediated activation of PPARγ is associated with increased neurogenic activity, as well as reduced reactive gliosis, in the granule cell layer of the hippocampal DG (Esposito et al., [@B41]).

Therapeutic Insights From Preclinical Psychiatric Models {#s3}
========================================================

A considerable number of studies have reported the pro-neurogenic effects of CBD, and some among them have even related these with an eCB mechanism of action. But, can the pro-neurogenic effects of CBD account for some of its therapeutic applications? Answering this question requires specialized experimental strategies designed to rule out CBD pro-neurogenesis, leaving intact its other pharmacological mechanisms and so, fewer experiments have been conducted. Nonetheless, a handful of studies have addressed this question, presenting evidence for a potential implication in the protection against neurodegenerative diseases (Esposito et al., [@B41]), anxiety- and mood-related disorders (Campos et al., [@B24]; Fogaça et al., [@B43]), as well as drug addiction (Luján et al., [@B68]).

Neurodegenerative and ischemic conditions are among the circumstances in which hippocampal function can manifest greater impairments (Shah et al., [@B101]). It was Esposito et al. ([@B41]) who firstly reported the pro-neurogenic effect of CBD in a neuropathological disease model. In their work, they showed how CBD could restore the neuronal differentiation levels after β amyloid peptide inoculation in a rat model of Alzheimer's disease. This effect was shown dependent on the activation of PPARγ receptors. Significantly, when a PPARγ antagonist was co-administered, CBD did not induce neuronal differentiation and, consequently, its neuroprotective effects were prevented (Esposito et al., [@B41]). Although suggestive, these results will need to be further verified, given the alternative protective consequences of PPARγ receptor activity by itself (Hughes and Herron, [@B49]). Anxiety- and mood-related disorders symptomatology is also critically dependent on hippocampal function (Anacker and Hen, [@B6]). For this reason, Campos et al. ([@B24]) tested if the action of CBD on hippocampal neurogenesis accounted for its anxiolytic and antidepressant effects. Using a genetic-pharmacological approach, they were able to report that the blockade of adult neurogenesis accounted for the anxiolytic and antidepressant effects of CBD on the elevated plus-maze and novel suppressed feeding tests. Using a more indirect approach, Fogaça et al. ([@B43]) have recently supported these implications. The co-administration of CBD and a CB1 or CB2 antagonist prevented both the increase in adult hippocampal neurogenesis and the anxiolytic effects of CBD. Again, this pharmacological strategy does not allow to discard beneficial changes induced by CB1 or CB2 receptor activity by itself, but the replication of the causal discovery of Campos et al. ([@B24]) is certainly meaningful. Finally, our group also tried to unravel the participation of adult neurogenesis in the protective actions of CBD on cocaine self-administration, a rodent model of cocaine abuse. Based on the findings that CBD-induced attenuation of cocaine voluntary intake was accompanied by increased adult neurogenesis, as well as MAPK/CREB pathway activity in the hippocampus (Luján et al., [@B69]), we developed a pharmacological strategy aimed to prevent the increases in adult neurogenesis induced by CBD with the anti-mitotic agent temozolomide (Niibori et al., [@B79]). Similar to Campos et al. ([@B24]), we found that such an increase was crucially required by CBD to reduce cocaine voluntary intake in mice (Luján et al., [@B68]). Overall, available data supports that CBD-induced adult neurogenesis can account for the protective effects of CBD in certain psychiatric conditions. The role of CBD neurogenesis in other mental diseases remains largely unexplored. The case of schizophrenia is especially suggesting. Decreased hippocampal neurogenesis is observed in schizophrenic patients compared with control subjects (Reif et al., [@B89]), and it is rescued by atypical antipsychotics in rodents (Kusumi et al., [@B57]). Noteworthy, the pro-neurogenic effects of CBD in mice exposed to chronic unpredictable stress suggestively resembles that of atypical antipsychotics such as clozapine in the same model (Campos et al., [@B24]; Chikama et al., [@B30]; Morais et al., [@B75]; Fogaça et al., [@B43]). Based on this observation, studies dissecting the importance of CBD pro-neurogenic effects on its antipsychotic properties are promising, as well as highly needed.

Conclusion and Future Directions {#s4}
================================

A significant amount of animal and human data has emerged relating the neuro-modulatory role of adult hippocampal neurogenesis, its interactions with broader hippocampal circuits, and its implications on altered behaviors in different neuropsychiatric disorders (Beckervordersandforth and Rolando, [@B13]). Meanwhile, some pro-neurogenic compounds have been experimentally employed to counteract maladaptive neuroplasticity and improve hippocampal function. In the last decade, there has been an increased interest in the psychiatric therapeutic potential of CBD. Its protective brain effects, as well as its endocannabinoid mechanisms, have been related to its ability to facilitate the survival and differentiation of newborn neurons of the DG. Crucially, key studies have emerged linking this pro-neurogenic effect with reduced anxiety-like states and improved emotional and motivational processing in animal models of stress-, mood-, and substance use-related disorders. Albeit convincing, investigations of CBD's pro-neurogenic effects are still in an early stage, and further experimental efforts are required to answer several open questions. Only two studies have so far fully addressed the causal implication of such a CBD mechanism (Campos et al., [@B24]; Luján et al., [@B68]). This lack of studies also leads to several replication needs. For example, most of the work has been developed in male mice, which hinders possible interpretations regarding sex- or species-specific effects. Also, evidence regarding the effects of CBD in the pre-mitotic stages of neuronal proliferation is scarce. On the other end, we still lack a direct electrophysiological confirmation of the functional integration of maturing neurons in conditions of elevated neurogenic state induced by CBD. Answering such a question is vital to clarify the functional relevance of CBD-induced neurogenesis and rule out an epiphenomenon effect. From a theoretical perspective, we also needed to better conceptualize the therapeutic potential of increased neurogenic states in adults. Newborn neurons necessarily remodel hippocampal circuitries upon functional integration. Thus, increased neurogenesis can destabilize consolidated memories (Chambers et al., [@B27]; Deisseroth et al., [@B33]), which may promote forgetting (Akers et al., [@B3]; but see Epp et al., [@B40]). Finally, indirect information supportive of the occurrence of hippocampal neurogenesis in humans treated with CBD is not yet available. Measures of the 1.28 ppm neurogenesis-specific peak using magnetic resonance spectroscopy (Manganas et al., [@B71]) could be incorporated in future clinical trials working with CBD treatments to shed more light on the functional and therapeutic relevance of these CBD's neurogenic changes.
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